Researchers at Boston Children's Hospital and Harvard Medical School report a striking preclinical advance: an engineered liposome formulation that prolonged tetrodotoxin-induced sciatic nerve block in rats from hours to days or weeks. Led by Yuan Wang, PhD, and Daniel S. Kohane, MD, PhD, the team published the findings on Sept. 23, 2026, in Nature Biomedical Engineering. These are animal experiments, not an approved human therapy.
How The Delivery System Works
Liposomes are microscopic vesicles made of lipid bilayers and are commonly used to encapsulate and deliver drugs. The release rate of a hydrophilic drug typically depends on membrane composition and structure. In this study, the investigators used highly unsaturated phospholipids, which unexpectedly self-organized into multiple concentric bilayers rather than a single spherical vesicle.
The result is a "matryoshka" or nested architecture: each additional bilayer forms another barrier that a water-soluble molecule must cross before reaching surrounding tissue. The team proposes that these extra barriers substantially slow diffusion of the encapsulated drug, producing an ultra-sustained release.
Key Experimental Findings
- The liposomes were loaded with tetrodotoxin (TTX), a potent neurotoxin that blocks nerve conduction at very small doses.
- Median sensory recovery times in rat sciatic nerve blocks were reported as:
- 80 µg: ≈ 6.5 days
- 200 µg: ≈ 11 days
- 260 µg: ≈ 13 days (with full sensation returning over ~2–3 weeks)
- A commercial comparator formulation produced nerve blocks of approximately 4–8 hours.
- The authors reported no local or systemic toxicity in the tested animals at these dose levels under the study conditions.
- Reported durations are median recovery milestones and do not imply uninterrupted, complete anesthesia for the entire interval.
Potential And Important Caveats
This nested-liposome architecture is a promising platform for extended perioperative analgesia and might be adaptable to other hydrophilic therapeutics. Kohane noted potential applications in perioperative pain control and chronic pain, which could offer alternatives to opioid-based management if the approach proves safe and effective in humans.
Crucial cautions: Tetrodotoxin is a powerful neurotoxin. Absence of toxicity in these rat experiments reflects the specific formulation, dosing, and conditions tested and is not a general safety endorsement. No approvals exist for TTX as a clinical anesthetic based on the sources reviewed.
Translation to human use will require extensive additional work: long-term toxicology, dose optimization, immune-compatibility studies, scalable manufacturing, independent replication, and carefully controlled early-phase human trials with regulatory review. The authors did not identify independent replication of these results in the sources reviewed; independent confirmation will be an important next milestone.
Bottom Line
The Boston Children's / Harvard team demonstrated that a change in liposome architecture — nested bilayers formed from highly unsaturated phospholipids — can dramatically slow release of an encapsulated hydrophilic neurotoxin in rats, producing nerve blocks measured in days to weeks rather than hours. The finding is an important proof of concept for controlled-release drug delivery, but clinical relevance remains tentative until safety and efficacy are established in humans.
